News | Prostate Cancer | February 12, 2019

Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer

Promising early results of AI applied to micro-ultrasound for targeted biopsies could improve the speed at which prostate cancer is detected

Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer

February 12, 2019 — Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two companies work to improve the way prostate cancer is visualized and detected. Cambridge Consultants is applying deep learning to high-resolution micro-ultrasound imaging to identify potential suspicious regions of tissue and inform urologists who may want to consider this additional data in their biopsy protocol. Early results show real promise, according to the companies.

Prostate cancer is the second most common cause of cancer death in men in both the U.S. and the U.K. The current standard-of-care ultrasound, which guides prostatic needle biopsies that help to diagnose prostate cancer, yields a 30 percent false negative rate as the resolution of the ultrasound systems is insufficient to differentiate suspicious regions. As such, the prostate biopsies are usually delivered in a systematic, “blind” pattern. 1

The ExactVu micro-ultrasound platform is an imaging tool to allow urologists to harness micro-ultrasound’s near microscopic resolution in order to visualize suspicious regions and actually target their biopsies to those regions. Operating at 29 MHz, the micro-ultrasound provides a 300 percent improvement in resolution over conventional ultrasound.

Cambridge Consultants aims to use higher resolution micro-ultrasound images from the ExactVu platform in combination with cutting-edge artificial intelligence (AI) techniques to provide new information to urologists to help them to improve their targeting of prostate biopsies. With their AI tools being able to interrogate the full ultrasound data set when correlated to pathology, the analysis should deliver improved accuracy and better characterization of suspicious regions. The machine learning approach being applied is faster and less computationally intensive than traditional statistical approaches and may ultimately form the backbone of a commercially-viable software application. Early results from proof of concept testing show significant promise, even with relatively limited data sets.

The current work on prostate cancer is the latest output from Cambridge Consultants’ Digital Greenhouse 2, an experimental environment where data scientists and engineers explore and develop machine learning and deep learning techniques. Digital Greenhouse 2 aims to ensure that deep learning is potent beyond the huge online datasets that have powered advances to date. Recent work has focused on applying deep learning in areas where massive datasets are unavailable. In the case of its work on prostate cancer, data was available for hundreds of patients.

For more information: www.cambridgeconsultants.com, www.exactimaging.com

Related Content

Collaboration will include data sharing, R&D and an upgrade of RadNet’s fleet of mammography systems to Hologic’s state-of-the-art imaging technology
News | Breast Imaging | August 06, 2020
August 6, 2020 — RadNet, Inc., a national leader in providing hig
Intelerad Medical Systems, a leader in enterprise workflow solutions, announced the acquisition of Radius, a private cloud platform provider based in the Nashville, Tenn., metropolitan area.
News | Enterprise Imaging | August 05, 2020
August 5, 2020 — Intelerad Medical Systems, a leader in enterprise workflow solutions, announced the acquisition of
Keeping the health and safety of of the HIMSS audience in mind, the conference moves to August 9-13 in Las Vegas
News | HIMSS | August 03, 2020
August 3, 2020 —  The Healthcare Informatio...
Franco Fontana, CEO of the Esaote Group, and Xie Yufeng, Chairman of WDM.

Franco Fontana, CEO of the Esaote Group, and Xie Yufeng, Chairman of WDM.

News | Digital Radiography (DR) | July 31, 2020
July 31, 2020 — In the thick of the COVID-19 eme
Candelis, Inc., a leading provider of innovative and cost-effective enterprise healthcare solutions, and VasoTechnololgy, a subsidiary of the Vaso Corporation, announced an agreement to distribute Candelis' suite of image management PACS solutions and cloud services, including ImageGrid, ImageGrid Mini PACS and ASTRA Cloud.
News | Enterprise Imaging | July 29, 2020
July 29, 2020 — Candelis, Inc., a leading provider of innovative and cost-effective enterprise healthcare solutions,
Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

News | Prostate Cancer | July 28, 2020
July 28, 2020 — A study published in